Loading ETF profile…
The fund, under normal circumstances, invests at least 80% of its assets in the securities that comprise the index or investments with economic characteristics similar to the securities included in the index. The index provides exposure to the performance of companies, publicly listed in the United States, Canada and Europe, that are leading the development and application of messenger RNA (“mRNA”) technology. The fund is non-diversified.
Sector exposure data isn't available for this fund yet.
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | 8.09% | $253.12K |
| BGNE | BeiGene Ltd | 7.51% | $235.01K |
| ARCT | Arcturus Therapeutics Holdings Inc | 7.45% | $233.02K |
| SCLX | SCLX | 6.82% | $213.21K |
| ALNY | Alnylam Pharmaceuticals Inc | 6.45% | $201.64K |
| PTCT | PTC THERAPEUTICS INC USD 0.001 | 6.31% | $197.43K |
| BNTX | BIONTECH SE | 5.76% | $180.20K |
| MRNA | Moderna Inc | 5.60% | $175.01K |
| SRPT | SAREPTA THERAPEUTICS INC | 5.30% | $165.79K |
| MRVI | Maravai LifeSciences Holdings Inc | 4.93% | $154.25K |
| NTLA | Intellia Therapeutics Inc | 4.33% | $135.42K |
| IONS | IONIS PHARMACEUTICALS INC | 4.10% | $128.19K |
| ARWR | ARROWHEAD PHARMACEUTICALS IN | 3.68% | $115.07K |
| RNA | AVIDITY BIOSCIENCES INC | 3.67% | $114.74K |
| CVAC | CureVac NV | 3.38% | $105.80K |
| DYN | DYNE THERAPEUTICS INC | 3.05% | $95.32K |
| ABUS | ARBUTUS BIOPHARMA CORP NPV | 3.00% | $93.81K |
| SGMO | Sangamo Therapeutics Inc | 2.26% | $70.80K |
| STOK | Stoke Therapeutics Inc | 1.95% | $60.86K |
| GRTS | Gritstone Oncology Inc | 1.94% | $60.72K |
| HLVX | HLVX | 1.57% | $49.21K |
| PRQR | PROQR THERAPEUTICS NV | 1.54% | $48.13K |
| PEPG | PEPGEN INC | 1.29% | $40.48K |